Insider filing · ASMB

Gilead Sciences, Inc. bought $20.1M of Assembly Biosciences (ASMB)

Executed Dec 19 2024, disclosed Dec 23 2024, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Dec 23 2024), the stock returned -5.3% (delay-adjusted); from the execution session (Dec 19 2024), -6.6%. Derived: entry at the session's open, exit at the close 20 sessions later.

GI Gilead Sciences, Inc. 10% owner profile →

Gilead Sciences, Inc. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in ASMB. Across 1 priced purchase filing, the average 21-session return was +7.0% from execution and +30.6% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 56 days.

ASMB ASMB ASMB · 4 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→